Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome

Commentary
Video

The chief medical officer of Encoded Therapeutics overviews the company’s timeline and strategy for its gene regulation program for Dravet syndrome.

"What our team did is they develop an engineered transcription factor that upregulates the expression of the healthy allele in patients who have Dravet syndrome. And one important characteristic is that it's... not only gene selective, but cell selective. And we're targeting expression of these transgene in GABAergic inhibitory interneurons, because there's a whole body of literature indicating the importance of the cells in the pathophysiology of the disease. So, this is a precision medicine approach that is targeted to reestablish that balance between inhibition and excitation.”

Encoded Therapeutics is continuing to develop and evaluate its lead gene regulation therapy, ETX-101, for the potential treatment of people with SCN1A -positive Dravet syndrome. The company announced in February that it had secured clearance for clinical trials evaluating ETX-101 in this population in the United States, United Kingdom, and Australia.1,2

CGTLive® spoke with Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, to learn more about ETX-101 and what differentiates it from other novel genetic therapies in the investigational field. He shared that the company should soon be initiatingthe clinical trials. He also gave an overview of the company’s strategy with its Dravet program, including the clinical trials, sharing data from natural history studies that Encoded has conducted, and connecting with patient advocacy groups to better understand what endpoints represent clinically meaningful changes for patients with Dravet and better inform clinical trial design.

REFERENCES
1. Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101. News release. Encoded Therapeutics. February 26, 2024. https://encoded.com/press-releases/encoded-therapeutics-announces-uk-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/
2. Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101. News release. Encoded Therapeutics. February 6, 2024. https://encoded.com/press-releases/encoded-therapeutics-announces-us-ind-clearance-and-australian-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.